Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Dong Dai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinases, Mice, Inbred BALB C. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences, Tianjin Municipal Science and Technology Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cyclin-dependent kinase 19 (CDK19) is overexpressed in prostate cancer, making it an attractive target for both imaging and therapy. Since little is known about the optimized approach for radioligands of nuclear proteins, linker optimization strategies were used to improve pharmacokinetics and tumor absorption, including the adjustment of the length, flexibility/rigidity, and hydrophilicity/lipophilicity of linkers. Molecular docking was conducted for virtual screening and followed by IC50 determination. Both BALB/c mice and P-16 xenografts were used for tissue distribution and PET/CT imaging. The ligand 68Ga-10c demonstrated high absorption in tumor 5 min after injection and sustains long-term imaging within 3 h. Furthermore, 68Ga-10c exhibited slow clearance within the tumor and was predominantly metabolized in both the liver and kidneys, showing the potential to alleviate metabolic pressure and enhance tissue safety. Therefore, the linker optimization strategy is well suited for CDK19 and provides a reference for the radioactive ligands of other nuclear targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Cl…
- Department of Molecular Medicine, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300308, China.
- Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China.
ORCID-Profile: Yu Zhao, Yiliang Li
Förderung
- Chinese Academy of Medical Sciences
- Tianjin Municipal Science and Technology Program
- National Natural Science Foundation of China
Zitieren
APA
Dai, D., Yu, J., Gou, W., Yang, S., Li, Y., Wang, Z., Yang, Z., Huang, T., Li, P., Zhu, T., Hou, W., Zhao, Y., Xu, W., & Li, Y. (2024). Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00281
Vancouver
Dai D, Yu J, Gou W, Yang S, Li Y, Wang Z, et al. Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00281
BibTeX
@article{Dai2024,
author = {Dai, Dong and Yu, Jiang and Gou, Wenfeng and Yang, Shuangmeng and Li, Yanli and Wang, Ziyang and Yang, Zhao and Huang, Ting and Li, Panfeng and Zhu, Tong and Hou, Wenbin and Zhao, Yu and Xu, Wengui and Li, Yiliang},
title = {Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00281}
}
EUVIMED